Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048550 | 0.86 | MMP2 (0.37) | MMP1MMP2MMP9MMP8SMN1; SMN2 | |
| SCHEMBL18048549 | 0.86 | MMP2 (0.37) | MMP1MMP2MMP9MMP8SMN1; SMN2 | |
| SCHEMBL15159359 | 0.83 | KDM4E (0.43) | ADAM17MMP1MMP2MMP9MMP8 | |
| SCHEMBL18272886 | 0.82 | MMP1 (0.38) | ADAM17MMP1MMP2MMP9MMP8 | |
| SCHEMBL12859785 | 0.81 | ADAM17 (0.44) | ADAM17MMP1MEN1KMT2AMMP9 | |
| SCHEMBL18924556 | 0.81 | ADAM17 (0.44) | ADAM17MMP1MEN1KMT2AMMP9 | |
| SCHEMBL18272888 | 0.76 | GNPAT (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13888696 | 0.74 | MEN1 (0.50) | ADAM17MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13596361 | 0.74 | MEN1 (0.50) | ADAM17MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5491769 | 0.72 | MEN1 (0.46) | ADAM17MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | ADAM17 2765/4885MMP1 1567/4885MEN1 1809/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | ADAM17 46/4885MMP1 193/4885MEN1 1660/4885 |
| US-10022453-B2 | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | KIF5B, KIF23, KIF2C | ADAM17 3446/4885MMP1 2278/4885MEN1 2184/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | ADAM17 3875/4885MMP1 3063/4885MEN1 1837/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | ADAM17 386/4885MMP1 2024/4885MEN1 1711/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | ADAM17 3446/4885MMP1 2278/4885MEN1 2184/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | ADAM17 249/4885MMP1 1728/4885MEN1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.